Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955640 · ClinicalTrials.gov registry record · Phase 1
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
A Phase 1 study, sponsored by Thomas Jefferson University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03955640: Clinical Trial Phase 1 study, sponsored by Thomas Jefferson University.
NCT03955640 is a Phase 1 study that was terminated before completion, run by Thomas Jefferson University. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03955640, a Phase 1 study, was terminated before completion, sponsored by Thomas Jefferson University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of olaparib when given with hyperthermia in treating patients with breast cancer that has come back in the chest wall. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hyperthermia treatment may kill or damage tumor cells by heating them to several degrees above normal body temperature. Giving olaparib and hyperthermia treatment may work better in treating patients with breast cancer that has come back in the chest well compared to standard of care.
Primary Outcome
Will be continually assessed according to the National Cancer Institute Common Toxicity Criteria for Adverse Advents (CTCAE version \[v\]5.0).
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Olaparib
- OTHER Questionnaire Administration
- PROCEDURE Hyperthermia Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2021-08-26 |
| Phase | Phase 1 |
Why NCT03955640 stopped before completion
NCT03955640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03955640 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03955640 about?
NCT03955640 is a clinical study titled "Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences". This phase I trial studies the side effects and best dose of olaparib when given with hyperthermia in treating patients with breast cancer that has come back in the chest wall. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hyperthermia treatment ...
What is the current status of trial NCT03955640?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2019-05-20. Estimated completion is 2021-08-26.
What interventions are being tested in trial NCT03955640?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Olaparib (DRUG), Questionnaire Administration (OTHER), Hyperthermia Treatment (PROCEDURE).
Who is sponsoring clinical trial NCT03955640?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03955640's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI